Quantum BioPharma Adds Anti-Corruption Financial Expert to Board Advisory Team

Quantum BioPharma Ltd. has expanded its Board of Directors' advisory capabilities by appointing Kevin Malone, a prominent financial advisor with over four decades of wealth management experience. Malone's appointment signals the company's commitment to enhanced corporate governance and shareholder protection strategies.

As the founder of Malone Wealth, Malone brings significant expertise in market pattern recognition and a strong advocacy background against trading manipulation. His professional mission aligns closely with Quantum BioPharma's corporate values, particularly in promoting financial transparency and protecting shareholder interests.

Malone's reputation for championing financial literacy and speaking out against naked short selling represents a strategic addition to the company's leadership perspective. His expertise could provide valuable insights as Quantum BioPharma continues developing innovative therapeutic solutions for neurodegenerative and metabolic disorders.

The appointment comes as the company advances its research portfolio, including its lead compound Lucid-MS, which shows potential in preventing and reversing myelin degradation associated with multiple sclerosis. Malone's financial acumen may help guide the company's strategic investments and financial decision-making processes.

Beyond its core research initiatives, Quantum BioPharma maintains a diverse portfolio, including strategic investments through its subsidiary FSD Strategic Investments Inc. and a partial ownership stake in Celly Nutrition Corp., which markets the UNBUZZD™ product.

Malone's addition to the advisory board underscores Quantum BioPharma's ongoing commitment to robust corporate governance, market transparency, and shareholder value creation in the dynamic biopharmaceutical sector.